Company intelligence / Profile preview

Tibet Haisco Pharmaceutical

Shannan, Tibet Autonomous Region, China

Ownership: Private
Employees: ~5300
Development stage: Commercial

Overview

Haisco has a robust R&D program with more than 65 new projects in innovative drugs and high-end generics across multiple therapeutic areas. The company has successfully commercialized several innovative products such as ciprofol injection for anesthesia and sedation. As of June 2025, the pipeline includes at least nine Category 1 new drugs under development with clinical-stage assets up to Phase 2.

Therapeutic areas: OncologyEndocrinologyImmunologyHematologyNeurology
Modalities: Small moleculeRecombinant polypeptideChemical drugs
Industry: Biotech

Partnerships

Chiesi Farmaceutici S.p.A.: Licensing agreement for novel dipeptidyl peptidase 1 inhibitor outside China for respiratory indications

Beyond the preview

Go deeper on Tibet Haisco Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tibet Haisco Pharmaceutical.

Explore the full profile